Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil

This publication has 19 references indexed in Scilit:

• Gene Expression for Dihydropyrimidine Dehydrogenase and Thymidine Phosphorylase Influences Outcome in Epithelial Ovarian Cancer
  Journal of Clinical Oncology, 2000
• Dihydropyrimidine Dehydrogenase and Messenger RNA Levels in Gastric Cancer: Possible Predictor for Sensitivity to 5-Fluorouracil
  Japanese Journal of Cancer Research, 2000
• The Role of Tegafur/Uracil in Pulmonary Malignancy
  Drugs, 1999
• Advantage of post-operative oral administration of UFT (Tegafur and Uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC)1
  European Journal of Cardio-Thoracic Surgery, 1998
• Pilot study of UFT combined with 5 consecutive days cisplatin in non-small cell lung cancer.
  Lung Cancer, 1997
• 118 Early phase II study of biochemical modulation chemotherapy (BCM) using 5-fluorouracil (5-FU) and cisplatin (CDDP) for advanced non-small cell lung cancer (NSCLC)
  Lung Cancer, 1997
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
  BMJ, 1995
• Thymidylate synthase and drug resistance
  European Journal Of Cancer, 1995
• A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study)
  European Journal of Surgical Oncology, 1995
• A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil
  European Journal Of Cancer, 1994